MMEA
IMNM icon

Main Management ETF Advisors’s Immunome IMNM Stock Holding History

Main Management ETF Advisors’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-76,944
Closed -$716K – 157
2025
Q2 		$716K Buy
76,944
+1,248
+2% +$10.2K 0.03% 117
2025
Q1 		$509K Buy
+75,696
New +$726K 0.02% 129

Other funds holding IMNM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Main Management ETF Advisors's IMNM Position: Q3 2025 in Review

Main Management ETF Advisors sold out of Immunome (IMNM) in Q3 2025, closing a stake of 76,944 shares — an estimated $716K sold.

Main Management ETF Advisors first reported a position in IMNM in Q1 2025 and held it in 2 quarters. The position peaked at $716K in Q2 2025. 153 funds tracked by Wall St. Rank hold IMNM as of Q3 2025.

  • Main Management ETF Advisors reported no remaining Immunome position as of Q3 2025 after selling out during the quarter.
  • Main Management ETF Advisors sold 76,944 Immunome shares in Q3 2025, an estimated $716K.
  • Main Management ETF Advisors first reported a position in Immunome in Q1 2025 and held it in 2 quarters.
  • Main Management ETF Advisors's Immunome position peaked at $716K in Q2 2025.
  • 153 funds tracked by Wall St. Rank held Immunome as of Q3 2025.

Based on Main Management ETF Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.